Roy Baynes Sells 9,750 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) Director Roy Baynes sold 9,750 shares of the company’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $44.22, for a total value of $431,145.00. Following the transaction, the director owned 37,500 shares of the company’s stock, valued at approximately $1,658,250. The trade was a 20.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Price Performance

Shares of TVTX opened at $44.80 on Wednesday. The company has a market cap of $4.14 billion, a P/E ratio of -194.77 and a beta of 1.13. The stock has a fifty day moving average price of $32.31 and a 200 day moving average price of $32.71. The company has a debt-to-equity ratio of 2.71, a current ratio of 2.74 and a quick ratio of 2.70. Travere Therapeutics, Inc. has a 12 month low of $13.88 and a 12 month high of $48.61.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings results on Monday, May 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.29. Travere Therapeutics had a negative return on equity of 28.38% and a negative net margin of 4.00%.The company had revenue of $127.20 million during the quarter, compared to analysts’ expectations of $136.23 million. During the same quarter in the prior year, the business posted ($0.47) earnings per share. The company’s revenue for the quarter was up 55.6% compared to the same quarter last year. On average, research analysts forecast that Travere Therapeutics, Inc. will post -0.16 earnings per share for the current year.

Institutional Investors Weigh In On Travere Therapeutics

Hedge funds have recently modified their holdings of the stock. State of Wyoming purchased a new stake in shares of Travere Therapeutics during the fourth quarter valued at $37,000. Torren Management LLC purchased a new stake in shares of Travere Therapeutics during the fourth quarter valued at $38,000. Comerica Bank lifted its holdings in shares of Travere Therapeutics by 77.5% during the fourth quarter. Comerica Bank now owns 1,127 shares of the company’s stock valued at $43,000 after purchasing an additional 492 shares during the last quarter. Fifth Third Bancorp purchased a new stake in shares of Travere Therapeutics during the first quarter valued at $35,000. Finally, Smartleaf Asset Management LLC lifted its holdings in shares of Travere Therapeutics by 69.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company’s stock valued at $45,000 after purchasing an additional 487 shares during the last quarter.

Analyst Ratings Changes

Several research analysts have recently issued reports on TVTX shares. TD Cowen increased their price target on Travere Therapeutics from $45.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday. Wall Street Zen cut Travere Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. Citigroup increased their price target on Travere Therapeutics from $53.00 to $59.00 and gave the stock a “buy” rating in a research note on Tuesday. Canaccord Genuity Group upped their price objective on Travere Therapeutics from $47.00 to $56.00 and gave the company a “buy” rating in a report on Tuesday, April 14th. Finally, Wedbush upped their price objective on Travere Therapeutics from $53.00 to $55.00 and gave the company an “outperform” rating in a report on Tuesday. Ten investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $46.58.

Travere Therapeutics News Summary

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target on TVTX from $45 to $60 and holds a Buy rating, implying a sizable upside from current levels. This is a strong analyst endorsement that can support upward momentum. Benzinga
• Positive Sentiment: Corporate update: management highlighted the FILSPARI approval in FSGS, strong demand for FILSPARI in IgAN, and the restart of Phase 3 dosing for pegtibatinase — operational progress that supports longer-term revenue growth. BusinessWire
• Neutral Sentiment: Q1 results were mixed: revenue of ~$127.2M missed consensus (~$136.2M), though reported adjusted EPS outperformed some estimates (MarketBeat shows $0.05 vs est. -$0.24) and revenue grew ~55.6% YoY — investors should dig into GAAP vs. adjusted figures and guidance. Earnings Release / Slide Deck
• Neutral Sentiment: Full Q1 earnings call transcript is available for detail on commercial uptake, margin cadence, and R&D timelines — useful for judging whether recent momentum is sustainable. Seeking Alpha Transcript
• Negative Sentiment: Insider sale: director Roy Baynes sold 9,750 shares at an average of $44.22 under a pre-arranged Rule 10b5-1 plan, reducing his stake by ~20.6% — a planned sale but a potential psychological negative for some investors. InsiderTrades

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.